• Purity

  >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to chemoattract BaF3 mouse pro?B cells transfected with human CCR1. The ED    ₅₀ for this effect is 0.5-2 ng/mL.

• Source

  E. coli-derived Gly42-Ala116

• Accession #

• N-terminal Sequence    
  Analysis

  Gly42

• Predicted Molecular Mass

  8.3 kDa

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Data Images

Background: CCL6/C10

CCL6, also known as C10 and SCYA6, is an 11 kDa member of the MIP-I family of beta -chemokines. CCL6, along with CCL9, CCL15, and CCL23, belongs to the N6 subfamily of proteins that have an N-terminal extension relative to other beta -chemokines (1 - 4). The mouse CCL6 cDNA encodes a 116 amino acid (aa) precursor that includes a 21 aa signal sequence (5). Removal of an additional 20 aa at the N-terminal results in an 8 kDa protein (aa 42 - 116) and the transition from a weak CCR1 agonist to a dramatically more potent and efficacious macrophage chemoattractant (3, 6). The N-terminal region of CCL6 and other N6 subfamily chemokines is cleaved following incubation with synovial fluid from inflamed joints as well as with inflammation-associated proteases such as chymase, cathepsin G, and elastase (3). CCL6 is upregulated in activated macrophages at sites of inflammation (5, 7 - 10) and functions as a chemoattractant for additional macrophage influx (8, 9). The inflammatory cytokine IL-13 stimulates CCL6 production which then induces the release of CCL2, CCL3, and proteases involved in tissue repair (10). CCL6 expression is upregulated by the oncoprotein L-Myc but repressed by c-Myc. CCL6 induced by L-Myc promotes cellular transformation and the development of a tumorigenic phenotype (11). N-terminally truncated mouse CCL6 shares 77% and 64% aa sequence identity with rat CCL6 and mouse CCL9, respectively. A human orthologue for mouse CCL6 has not been identified. Conversely, CCL15 and CCL23 and other members of the N6 subfamily have been described in human but not in mouse.

• References:

1. Maurer, M. and E. von Stebut (2004) Int. J. Biochem. Cell Biol. 36:1882.

2. Trakatelli, C. et al. (2005) Int. J. Biol. Markers 20:197.

3. Berahovich, R.D. et al. (2005) J. Immunol. 174:7341.

4. Berger, M.S. et al. (1993) DNA Cell Biol. 12:839.

5. Orlofsky, A. et al. (1991) Cell Regul. 2:403.

6. Berger, M.S. et al. (1996) Cytokine 8:439.

7. Orlofsky, A. et al. (1994) J. Immunol. 152:5084.

8. Kaesler, S. et al. (2002) Cytokine 3:157.

9. LaFleur, A.M. et al. (2004) Mediators Inflamm. 13:349.

10. Ma, B. et al. (2004) J. Immunol. 172:1872.

11. Yi, F. et al. (2003) Cancer Res. 63:2923.

• Entrez Gene IDs:

  20305 (Mouse); 287910 (Rat)

• Alternate Names:

  C10; CCL6; MRP-1; SCYA6